

Index

- A**
- A-1155463, 18
 - A-1331852, 18
 - A4LI. *See* Alliance for Longevity Initiatives
 - A β _{1–42}, 41
 - ABCs. *See* Age-associated B cells
 - “Active grandparent” hypothesis, 64
 - Activin A, 19
 - Acetyl CoA, 99
 - Acylcarnitines, 110
 - AD neuropathologic change (ADNC), 129–130
 - AD. *See* Alzheimer’s disease
 - Adenine diphosphate ribose (ADPR), 31
 - Adenine nucleotide transporter (ANT), 98, 101, 104
 - Adenosine triphosphate (ATP), 30, 98–99, 104, 108, 110, 215
 - ADIPOQ gene, 165
 - ADNC. *See* AD neuropathologic change; Alzheimer’s disease neuropathologic change
 - ADP ribosyl-cyclases
 - CD38, 31
 - CD73, 31
 - CD157, 31
 - ADPR. *See* Adenine diphosphate ribose
 - Adult immunization campaigns, 191–192
 - AG. *See* Applied genetics
 - Age-associated B cells (ABCs), 80
 - Aging
 - biology, 97–98
 - biomedical research, 55
 - evolutionary biodemography, 56–57, 119
 - humans in evolutionarily relevant environments, 63–64
 - metabolic rate theory, 167
 - negative effects, 55
 - pillars, 13
 - pleiotropic gene theory, 124
 - primates, 58–61
 - risk of death, 120
 - Taming Aging with Metformin (TAME), 170
 - Aging research
 - Amboseli Baboon Research Project, 60
 - comparative primate aging models, 61–63
 - cryptocurrency as a crowdfunding mechanism, 212–214
 - Developmental Theory of Aging, 56
 - Disposable Soma theory, 56
 - equity crowdfunding, 210–212
 - evolutionary principles, 55–56
 - evolutionary-relevant animal models, 57–58
 - Mutation Accumulation Theory, 55
 - AICAR, 110
 - Akkermansia*, 86
 - α -Klotho, 20, 25
 - Alliance for Longevity Initiatives (A4LI), 216
 - ALS. *See* Amyotrophic lateral sclerosis
 - Alzheimer’s disease (AD)
 - diagnosis
 - clinical, 130–131
 - pathologic, 131
 - psychometric tests, 130
 - early-onset familial forms, 133
 - lifestyle-based approaches, 138
 - progressive, 131
 - resistance and resilience
 - caveats of current definitions, 132–133
 - defined, 131–132
 - genetic mediators, 133–134
 - leveraging approved therapeutics to target pathways, 137–138
 - leveraging modifiable risk factors, 138–139
 - mechanisms, 133
 - modifiable mediators, 134–136
 - targeting underlying pathology, 136–137
 - symptoms
 - memory loss, 130
 - sleep disturbances, 138
 - treatments
 - disease-modifying, 136
 - effects of neuron dysfunction and loss, 137
 - therapeutic approaches, 136
 - Alzheimer’s disease neuropathologic change (ADNC), 129, 131–139
 - Amboseli Baboon Research Project, 60
 - Ambra1, 101
 - Amino acid tryptophan (Trp), 33–34
 - AMPK, 101, 104, 110, 167
 - Amyloid precursor protein (APP), 102, 131, 133
 - Amyloid β (A β) plaques, 102, 129, 131, 137
 - Amyotrophic lateral sclerosis (ALS), 214
 - ANAVEX2-73, 104
 - Anemia, 61, 88
 - ANT. *See* Adenine nucleotide transporter
 - Antagonistic pleiotropy, 16, 55–56, 168–169
 - Anti-DPP4 antibodies, 19

Index

- Anti-IGF1R monoclonal antibodies, 169
APOC1 gene, 166
APOC-3 gene, 165, 169
APOE gene, 134, 166–167, 179, 181
APP. *See* Amyloid precursor protein
Applied genetics (AG), 177, 179
Aspirin in reducing events in the elderly (ASPREE), 88
ASPREE. *See* Aspirin in reducing events in the elderly
Astaxanthin (AX), 103–104
ATF4, 84–85, 100
ATF5, 100
ATP. *See* Adenosine triphosphate
Atherosclerotic disease, 88
Autophagy, 29, 31, 38, 42, 74, 77, 84, 101, 109–110, 138
AX. *See* Astaxanthin
- B**
- B1a cells, 86
B2M, 19
BACE1, 41
BALB/c, 102
Barnesiellaceae, 86
Bcl-2, 18, 41, 101
Bec-1 gene, 109
 β -carotene, 103
 β -galactosidase, 15
 β -oxidation, 30, 98–99
Bifidobacterium species, 86, 138
Bioceuticals, 229
Biogerontology, 225, 232
Biological time bombs, 3
Biomedicine, 233
Biotechnology projects, 209
Bitcoins, 208, 212, 214
Blautia, 87
Blockchain technology, 207–208, 212, 214–215, 217
Bone calcification, 124
Brain aging, 99, 130, 135, 139
Brain health campaigns, 191
BRCA gene, 166, 183
Butyrate, 86
Butyricimonas, 86
Butyrivibrio, 86
- C**
- C57Bl/6N, 38–39, 102
cADPR. *See* Cyclic ADP ribose
Caenorhabditis elegans, 37, 39–41, 100, 120, 231
Caloric restriction, 38, 58, 135, 138, 227
Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial, 88
CANTOS. *See* Canakinumab Anti-Inflammatory Thrombosis Outcome Study trial
Cardiolipin (CL), 74, 104
Caregiving
 demand and cost, 185
 models and solutions, 189
 older family members, 189
 responsibilities, 185
 support for those who care for older adults, 191
Carnitine palmitoyltransferase I (CPTI), 103
Carotenoid astaxanthin, 104
CART. *See* Chimeric antigen receptor T
CCFs. *See* Cytoplasmic chromatin fragments
CD4⁺ T cells, 77–78, 80–81, 84
CD9 receptor, 19
CD11c⁺, 80
CD21, 80
CD23, 80
CD28, 78, 80
CD38, 31, 35–36
CD73, 31
CD157, 31
CDK1/cycB inhibitor, 15
CDK2/cycE, 14–15
CDK4/cycD, 14–15
Cell-cycle arrest, 13, 15
Cell reprogramming, 227
Cellular senescence
 associated secretory phenotype, 16–17
 clinical trials, 21–22
 future perspectives, 24
 hallmarks, 15–16
 human studies, 19–20
 induction of, 14–15
Ceriodaphnia, 102
CETP. *See* Cholesteryl ester transfer protein
CGAS-STING, 16, 42, 47
Chimeric antigen receptor T (CART), 19
CHO oxidation, 103
Cholesteryl ester transfer protein (CETP), 165, 169
CHOP, 100
Christensenellaceae, 86
Chronic inflammation, 17, 46, 62–64, 71, 74–76, 86
Chronic neuroinflammation, 137
Chronic obstructive pulmonary disease (COPD), 20, 150, 162, 196
Chrysemys picta, 122
CL. *See* Cardiolipin
Clostridioides difficile infection, 87
Clostridium species, 86
Cognitive reserve, 131, 134–135
COPD. *See* Chronic obstructive pulmonary disease
Coprococcus, 87
Covid-19
 impacts, 190
 pandemic, 147, 149, 178
 vaccines, 195–196, 198
CPTI. *See* Carnitine palmitoyltransferase I
Crowdfunding, of aging science

- cryptocurrency, 212–214
 - equity, 210–212
 - “flexible funding” campaigns, 209
 - impact, 216
 - Jimmy Fund, 216
 - platforms
 - aging research, 210
 - uses, 209–210
 - publishing, 215–216
 - versus traditional funding, 208–209
 - Crowdsourcing
 - catalyst for advocacy and increased public funding, 216–217
 - decentralized science, 214–215
 - impact, 216
 - Cryptocurrency
 - crowdfunding mechanism for aging science, 212–214
 - global adoption, 212
 - PulseChain, 214
 - CSA. *See* CS complementation group A
 - CSB. *See* CS complementation group B
 - CS complementation group A (CSA), 37, 40
 - CS complementation group B (CSB), 37, 40
 - Curcumin, 18, 104, 110
 - CureDAO, 215
 - Cyclic ADP ribose (cADPR), 31
 - Cytochrome c, 101
 - Cytokines, 75, 78, 83
 - Cytoplasmic chromatin fragments (CCFs), 16
- D**
- Damage-associated molecular patterns (DAMPs), 47, 74–75, 101
 - DAMPs. *See* Damage-associated molecular patterns
 - DAOs. *See* Decentralized autonomous organizations
 - DASH. *See* Dietary approaches to stop hypertension
 - Data Protection Act (UK), 215
 - Dct-1* gene, 40, 109
 - Decade of Healthy Ageing, 193
 - Decentralized autonomous organizations (DAOs), 214
 - DeSci, 215
 - Developmental Theory of Aging, 56
 - Diabetes mellitus type 2 (T2DM), 161, 164
 - Diabetes Prevention Program (DPP), 164
 - Dietary approaches to stop hypertension (DASH), 138
 - Dietary restriction (DR), 124, 138
 - Diseases, age-related, 7–8, 57, 61, 97, 147, 164–165, 171, 226
 - Disposable Soma theory, 56, 124
 - Dorea*, 87
 - “Dorian Gray” slowdown, 153
 - DPP. *See* Diabetes Prevention Program
 - DR. *See* Dietary restriction
 - Drosophila*, 41, 102
 - Dysbiosis, age-related, 46, 71, 74, 86–87
- E**
- E2F, 14–15
 - EA. *See* Ellagic acid
 - ECM. *See* Extracellular matrix
 - eIF2 α . *See* Eukaryotic initiation factor 2 α
 - Elamipretide, 104–108
 - Electron transport system (ETS), 98–99
 - Ellagic acid (EA), 109
 - Ellagitannins (ETs), 109
 - Endoplasmic reticulum (ER), 84, 100
 - Enterobacteriaceae*, 86
 - Equity crowdfunding, for aging research, 210–212
 - ER. *See* Endoplasmic reticulum
 - Erc1*, 76, 83
 - Escherichia coli*, 121
 - Ethereum, 208, 212, 214
 - ETS. *See* Electron transport system
 - ETs. *See* Ellagitannins
 - Eubacterium*, 87
 - Eukaryotic cells, 98
 - Eukaryotic initiation factor 2 α (eIF2 α), 84
 - Evolutionary medicine, 56, 63
 - Exceptional longevity
 - age-delaying drugs, 168–170
 - genetics, 164–167
 - heritability, 163–164
 - protective genotypes, 165
 - rationale for studying, 161–163
 - Extracellular matrix (ECM), 17
- F**
- FADH₂, 98
 - Faecalibacterium* species, 86–87
 - Familial longevity, 164–168
 - FDI. *See* First dorsal interosseous
 - Fecal microbiota transplantation (FMT), 87
 - Financial wellness, 193
 - First dorsal interosseous (FDI), 108
 - FMT. *See* Fecal microbiota transplantation
 - Focused research organization (FRO), 198
 - FOXO3, 161, 166, 179, 181–182
 - FOXO4-p53, 18
 - FRO. *See* Focused research organization
 - FUNDC1, 101
 - Funding channels of geroscience
 - foundational foundations, 223
 - fundors, 222–224
 - investing in discoveries, 226–227
 - investing in people, 224–226
 - new philanthropists, 223–224
 - surge of investment, 224
 - tech billionaires, 223

Index

G

G₁, 14
G₁/S, 14–15
G₂/MDNA, 15
GCN2. *See* General control nonderepressible 2
General control nonderepressible 2 (GCN2), 84–85
Generic recommendations (GRs). *See* Retirement age, generic recommendations
Genome-wide association study (GWAS), 134, 165–167
Geroprotectors, 9, 209, 236
GeroScience Interest Group (GSIG), 223, 233
GH. *See* Growth hormone
GHR. *See* GH receptor
GH receptor (GHR), 167, 169
Glycoprotein nonmetastatic melanoma protein B (GPNMB), 19
Gompertz slope, 122–123
GPNMB. *See* Glycoprotein nonmetastatic melanoma protein B
GPR78, 166
Great apes, 61–62
Growth hormone (GH), 102, 120, 167, 171
GRs. *See* Retirement age, generic recommendations
GSIG. *See* GeroScience Interest Group
GWAS. *See* Genome-wide association study

H

Health gains, 156
Health Insurance Portability and Accountability Act 1996 (HIPAA), 215
Health Savings Accounts (HSAs), 191
Health span
 assessments, 180
 concept, 232
 current and future generations, 177
 extension of, 9, 17, 87, 104, 163
 longevity, 77
 meaning, 9, 232
Healthy aging
 age-related pathologies, 55
 biomarkers, 86
 importance, 190
 investment, 191–192
 mitochondrial-targeted interventions, 111
 promotion, 29, 64, 97, 138
 role for spermidine in, 109
 social gains, 153
 strategies, 193
 workplace, 191
Heat shock response (HSR), 74, 84
HEL. *See* Hexanoyl-lysine adduct
Hematopoiesis, 77
Hematopoietic stem cells (HSCs), 77
HEXA gene, 166
Hexanoyl-lysine adduct (HEL), 103

High-density lipoprotein (HDL), 46, 161, 165, 169
HIPAA. *See* Health Insurance Portability and Accountability Act 1996
HLE. *See* Life expectancy, healthy life expectancy
HOPE trial, 101
HPA. *See* Hypothalamic-pituitary-adrenal
HSAs. *See* Health Savings Accounts
HSCs. *See* Hematopoietic stem cells
HSR. *See* Heat shock response
Human inflammaging, 63
Human primary cells, subculturing, 13
Human senescence, 120–123
Hutchinson–Gilford progeria syndrome, 77, 162
Hydra spp., 119, 121–122, 125
Hyperphosphorylated Tau (pTau), 41, 129, 131
Hypertension, 46, 61, 63, 103, 137–138, 163, 170
Hypothalamic-pituitary-adrenal (HPA), 62

I

IFN. *See* Interferon
IGBP-3, 168
IGF-1. *See* Insulin-like growth factor 1
IL. *See* Interleukin
IMM. *See* Inner mitochondrial membrane
Immune dysregulation, age-associated, 78, 83
Immune responses, dysregulation, 78
Impact index fund, 212
Impaired oxidative phosphorylation, 100
Inflammaging
 age-related dysbiosis, 86–87
 immunosenescence, 78–84
 integrated stress response, 84–86
 pathology and accelerated aging
 attenuating chronic inflammation, 76–77
 inducing inflammation, 75–76
 underlying mechanisms, 72–75
Inflammation
 attenuation of, 76–77
 insulin resistance induced by, 74
 mitochondrial RNA/RIG-I-dependent, 39
 pathology and accelerated aging, 75–77
 “pillars” of aging, 72
 risk factor for chronic diseases, 87–89
 suppression, 75
Inner mitochondrial membrane (IMM), 83, 102, 104
Insulin-like growth factor 1 (IGF-1), 102, 161, 167–168
Integrated stress response (ISR), 71–72, 74, 85–86
Interferon (IFN)
 IFN-I, 16
 IFN- γ , 78
Interleukin (IL)
 Interleukin 1 (IL-1), 47, 76
 Interleukin 1 α (IL-1 α), 19–20
 Interleukin 1 β (IL-1 β), 86
 Interleukin 6 (IL-6), 19–20, 47, 76–77, 83–84, 86

Interleukin 8 (IL-8), 19
Interleukin 17 (IL-17), 17, 77–78, 80, 84
Interleukin 21 (IL-21), 17
Interleukin 23 (IL-23), 17
Intestinal bowel disease, 72
Intrinsic dysregulation, age-related, 71–72
IR. *See* ischemia reperfusion
Ischemia reperfusion (IR), 105–107
ISR. *See* Integrated stress response

J

J147, 104
JAK/STAT inhibitors, 16
JAK/STAT3 inhibitors, 19
Jimmy Fund, 216–217

K

Kynurenine pathway, 31–34

L

LabDAO, 215
Lactobacterium species, 138
Lamin B1, 20
LC. *See* Liquid chromatography
LDL. *See* Low-density lipoprotein
LEAF. *See* Lifespan Extension Advocacy Foundation
LGP. *See* Longevity Genes Project
Life expectancy
 compressing morbidity, 148
 global, 186
 healthy life expectancy (HLE), 150
 levels, 150
 new epidemiological transition and, 152–153
 rise in, 149
 survival curve, 154
 worldwide trend in, 195
Life extension
 arguments for and against, 5–7
 funding for research
 ARPA-Aging model, 199
 collaborations, 198
 failure, 203
 game-changing technologies, 197–198
 limitations, 203–204
 long-term, 201–203
 “moonshot” funding models, 196–197
 nongovernmental, 200–201
 supportive/preliminary data, 198–200
Life spans
 determination, 1
 human, 3–5
 Kirkwood’s disposable soma theory, 124
 origin, 1–2

 species-specific, 2–3, 124
Limits to life, mechanisms setting, 123–126
Liquid chromatography (LC), 35, 101
LLFS. *See* Long Life Family Study
Long Life Family Study (LLFS), 163, 165, 168
Longevity. *See also* Exceptional longevity
 assessing performance, 155–157
 economic tools to evaluate, 148
 evaluating gains to health, 148–150
 evolutionary basis, 121
 familial, 164, 167
 humanity’s quest, 7
 hyperpersonal longevity assessment tool, 179
 international gains, 153–155
 mathematical modeling, 121
 new epidemiological transition, 152–153
 new financial landscape, 185–188
 rationale for studying, 161–163
 role of *SIRT6*, 168
 targeting biological age, 150–152
 value of statistical life (VSL) framework, 148, 155
Longevity Genes Project (LGP), 163, 167
Low-density lipoprotein (LDL), 46

M

Mammalian target of rapamycin (mTOR), 16, 19, 84, 104, 167, 169
Matrix metalloproteinases (MMPs), 20
mCAT. *See* Mitochondrial catalase
MCI. *See* Mild cognitive impairment
Mcp1, 76
MDM2 inhibitor, 20
MDPs. *See* Mitochondrial-derived peptides
Mediterranean-DASH intervention for
 neurodegenerative delay (MIND), 138
Mendelian genetics, 161, 166
Metformin, 77, 110, 164, 170, 203, 228, 236
Microbiomes, 71–72, 74, 86–87, 109, 138
Mild cognitive impairment (MCI), 64, 138
MIND. *See* Mediterranean-DASH intervention for
 neurodegenerative delay
MiR146a, 77
Mitochondria
 calcium homeostasis and aging, 100
 double-membrane organelles, 97
 outer mitochondrial membrane (OMM), 101
 quality control in aging, 100–101, 108–110
 redox stress in aging muscle, 108
 role in aging biology, 97–98
Mitochondrial bioenergetics, 74, 98–99
Mitochondrial catalase (mCAT), 100
Mitochondrial-derived peptides (MDPs), 101, 110, 170
Mitochondrial dysfunction, 13–14, 25, 35–39, 42, 46, 76, 99–100, 138, 196
Mitochondrial metabolites, in aging, 99–100

Index

- Mitochondrial oxidative stress, 101
Mitochondrial permeability transition pore (mPTP), 100
Mitochondrial redox biology, 99
Mitochondrial targeted therapies
 astaxanthin (AX), 103–104
 biogenesis, 110
 elamipretide, 104–108
 mitochondrial quality control, 108–110
 mitoquinone (MitoQ), 102
 MitoTEMPO, 102–103
 Skq1, 102
Mitochondrial unfolded protein response (mUPR), 35,
 39, 42, 100
Mitophagy, 29, 31, 35, 37–42, 74, 89, 100–101, 108–110
Mitoquinone (MitoQ), 102
MitoSENS Mitochondrial Repair Project, 215
MitoTEMPO treatment, 102–103
MMPs. *See* Matrix metalloproteinases
Mono-ADP-ribosylase enzyme, 168
Mortality, age-specific, 121
Mortality rate, 6, 56, 120–123, 152–153, 158
MOTS-c, 101, 110
mPTP. *See* Mitochondrial permeability transition pore
mTOR. *See* Mammalian target of rapamycin
mUPR. *See* Mitochondrial unfolded protein response
Mutation Accumulation Theory, 55
- N**
- NA adenine dinucleotide phosphate (NAADP), 31
NAAD. *See* Nicotinic acid adenine dinucleotide
NAADP. *See* NA adenine dinucleotide phosphate
NAD⁺
 augmentation benefits, 38–42
 biosynthetic pathways, 32
 changes in age-associated diseases, 37–38
 changes during normal aging, 34–36
 changes in pathological aging, 37
 consuming enzymes, 30–31
 consuming proteins, 31
 supplementation, 42–46
NAD⁺ synthase (NADS), 33–34
NADH, 29–31, 33–35, 98–100
NADP. *See* Nicotinamide adenine dinucleotide phosphate
NADPH, 99
NADS. *See* NAD⁺ synthase
NAMN. *See* Nicotinic acid mononucleotide
NAMPT, 33, 36–37, 39, 42
Naproxen, 87
NaPRT. *See* Nicotinic acid phosphoribosyltransferase
National Cancer Act, 216
National Health and Nutrition Examination Survey
 (NHANES III), 167
National Institute on Aging (NIA)
 early days, 231–234
 Interventions Testing Program (ITP), 231
 Longevity Assurance Genes (LAG) initiative, 231
 request for applications (RFAs), 231
 development of geroscience, role in, 231–236
Natural killer T (NKT) cells, 78
Negative aging, 57
NEMO, 76
Neurofibrillary tangles (NFTs), 41, 129, 131
Neuroscience, 202, 233–234
NF- κ B inhibitors, 16, 19, 47, 71, 75–77, 85–86, 88
NFT. *See* Nonfungible cryptocurrency token
NFTs. *See* Neurofibrillary tangles
NHANES III. *See* National Health and Nutrition
 Examination Survey
NIA. *See* National Institute on Aging
Natural selection, 3, 16, 55–56, 121, 124, 126
Nicotinamide adenine dinucleotide (NAD). *See* NAD⁺
 and NADH
Nicotinamide adenine dinucleotide phosphate (NADP), 31
Nicotinamide mononucleotide (NMN), 30–34, 36–42,
 46, 100, 108, 215
Nicotinamide riboside (NR), 30–34, 38–42, 46, 100
Nicotinamide riboside kinases (NRK1-2), 32–33
Nicotinic acid adenine dinucleotide (NAAD), 34, 38–39
Nicotinic acid mononucleotide (NAMN), 33–34
Nicotinic acid phosphoribosyltransferase (NaPRT), 34
NKT cells. *See* Natural killer T cells
NLRP3, 42, 74, 88, 101
N-methyl-D-aspartate (NMDA) receptor, 137
NMDA receptor. *See* N-methyl-D-aspartate receptor
NMN. *See* Nicotinamide mononucleotide
NMNadenyl transferases 1–3 (NMNAT1–3), 32–34, 37
NMNAT1–3. *See* NMNadenyl transferases 1–3
Nonfungible cryptocurrency token (NFT), 214
Nonsteroidal antiinflammatory drugs (NSAIDs), 138
NOTCH receptor, 19
NOVOS, 215
NR. *See* Nicotinamide riboside
NRF2, 101
NRK1–2. *See* Nicotinamide riboside kinases
NSAIDs. *See* Nonsteroidal antiinflammatory drugs
Nutraceuticals, 103, 215, 229
- O**
- Odoribacter*, 86
Olaparib, 40
OMM. *See* Mitochondria, outer mitochondrial membrane
Open Longevity, 215
OpenCures, 215
Oscillospira, 86
Oxidative phosphorylation, 98–100
- P**
- P7C3, 42
P16^{INK4a}, 14–20, 24

P21^{CIP1/WAF1}, 14–20, 24
P38-MAPK inhibitors, 16, 19
P50, 75–76
P53, 14–16, 18–19
P65, 75
PAPR-1, 165
PARP. *See* Poly ADP-ribosylation
Pathologies, age-related, 55
Pattern-recognition receptors (PRRs), 47
PD. *See* Parkinson's disease
PERK. *See* PKR-like ER kinase
Pink-1 gene, 109
PKR. *See* Protein kinase R
PKR-like ER kinase (PERK), 85
Placebo-controlled clinical trial, 170, 210, 236
Podospora, 102
Poly ADP-ribosylation (PARP), 31, 35, 37, 39–40
Polygenic risk scores (PRS), 134, 165
PON1, 165
Porphyromonas gingivalis, 86
Parkinson's disease (PD), 14, 29, 100, 214
Positive-wealth span, 182
Preiss–Handler pathway, 30–34
Presenilin 1 gene, 133
Presenilin 2 gene, 133
Proinflammatory mediators, 71, 77, 84
PROTACs. *See* Proteolysis-targeting chimeras
Protein kinase R (PKR), 85
Proteolysis-targeting chimeras (PROTACs), 18–19
PRRs. *See* Pattern-recognition receptors
PRS. *See* Polygenic risk scores
Psychometric tests, 130
pTau. *See* Hyperphosphorylated Tau
PVLR2 gene, 166

Q

QALY. *See* Quality-adjusted life years
Quality-adjusted life years (QALY), 149
Quality of life, 9, 97, 138, 149, 181, 193, 232, 235–236
Quantity of life, 149, 235
Quercetin (Q), 18, 20

R

Rapamycin, 76–77
Rb. *See* Retinoblastoma protein
RelA, 76
Retinoblastoma protein (Rb), 14–15
Retirement age
 generic recommendations (GRs)
 case study, 180, 182
 generic advisor recommendation, 181–182
 goal of financial planning, 181
 guidance on when to draw social security, 179–180
 limitations, 182–183

 long-term care, 180–181
 portfolio risk, 181
 product mix, 181
 working and learning beyond, 188–189
Return-on-investment (ROI), 201–202, 208
Rheumatoid arthritis, 72, 77–78, 80, 88
ROI. *See* Return-on-investment
Roseburia, 87

S

SA- β gal, 15, 19–20, 24
Salvage pathway, 31–34
SAMP8, 99, 104
Sarcoplasmic reticulum, 100
SARM1, 31
SARS-CoV-2 S-antigen, 16
SASP. *See* Senescence-associated secretory phenotype
SCAPs. *See* Senescent cell antiapoptotic pathways
Senescence-associated secretory phenotype (SASP),
 16–20, 25, 74, 76, 80, 83
Senescent cell antiapoptotic pathways (SCAPs), 18–19
Senolytics, 17–19, 20, 24–25, 227, 236
Ser202, 41
Shigella flexneri, 86
SHLP2-3, 110
SHLPs1-6, 110
Single-nucleotide polymorphisms (SNPs), 165–167
Single-nucleotide variants (SNVs), 125, 165
SIR2, 30
SIRT6. *See* Sirtuins
Sirtuins (SIRT6), 31
 SIRT1, 35, 37, 39, 40
 SIRT3, 36
 SIRT6, 168
Skn-1 gene, 109
SkQ1 treatment, for life span extension, 102
SLC. *See* Solute carrier
Sleep disturbances, 138
Slowdown in aging, value of, 154, 158, 196
SNPs. *See* Single-nucleotide polymorphisms
SNVs. *See* Single-nucleotide variants
Social competition, in primates, 60
Social safety nets, 183
Social security, 179–180, 183
SOD2. *See* Superoxide dismutase
Solute carrier (SLC)
 SLC7A5, 33
 SLC25A51, 33
 SLC25A52, 33
 SLC36A4, 33
Somatic mutations, 125–126
Spermidine, 101, 109
Sqst-1 gene, 109
SR12343, 76
SRT1720, 40

Index

SS peptides. *See* Szeto–Schiller peptides
Stem cell aging, 232
Stimulator of interferon gene (STING) pathways, 101
STING. *See* Stimulator of interferon gene pathways
SToMP-AD, 20
Streptococcus, 86
Superoxide dismutase (SOD2), 99
Szeto–Schiller peptides, 104

T

T2DM. *See* Diabetes mellitus type 2
TAFs. *See* Telomere-associated DDR foci
TAME. *See* Taming Aging with Metformin
Taming Aging with Metformin (TAME), 170, 198, 203, 228, 236
Targeting aging, 147, 150–152, 155, 157, 196, 227
Tay–Sachs disease, 166
TBI. *See* Traumatic brain injury
TCA. *See* Tricarboxylic acid cycle
Telomere-associated DDR foci (TAFs), 15
TGN. *See* Translational Geroscience Network
THC. *See* Transhuman Coin token transactions
Thr181, 41
Thr205, 41
Thr231, 41
Thyroid-stimulating hormone (TSH), 167
Thyroid-stimulating hormone receptor (TSHR), 167
TIFs. *See* Telomere-induced DNA damage foci
TLR. *See* Toll-like receptor
TMTC2 gene, 166
Toll-like receptor (TLR)
 TLR 7, 80
 TLR 9, 80
TOMM40 gene, 166
TPP⁺. *See* Triphenylphosphonium ion
Transhuman Coin token (THC) transactions,
 212, 214
Translational Geroscience Network (TGN), 23–24, 226
Transporter connexin 43 (Cx43), 31
Traumatic brain injury (TBI), 136
Tricaprilin, 104
Tricarboxylic acid cycle (TCA), 98–100
Trimethylamine, 87
Triphenylphosphonium ion (TPP⁺), 102–103
TSH. *See* Thyroid-stimulating hormone
TSHR. *See* Thyroid-stimulating hormone receptor
Tumor necrosis factor- α , 47, 74, 76–78, 83–84, 87–88
Turritopsis nutricula, 122

U

UA. *See* Urolithin A
UBX101, 20

Unfolded protein response (UPR), 35, 74, 84, 100
uPAR. *See* Urokinase-type plasminogen activator
 receptor
UPR. *See* Unfolded protein response
Urokinase-type plasminogen activator receptor
 (uPAR), 19
Urolithin A (UA), 41, 101, 109–110
USP42 gene, 166

V

Vps-34 gene, 109

W

War on Cancer, 216
Wealth management
 age of longevity, 185–188
 challenges, 185
 Covid-19, impacts and lessons, 190
 efficient, equal caregiving, 189
 financial wellness, 186, 188–189
 individual, 192–193
 labor market, 187
 “Life Plan” tool, 192
 maximization of financial security, advances in
 geroscience, 188
 relation with health, 188
 role of financial services industry
 “financial gerontology” training, 192
 financial tools to pay for longer
 lives, 192
 needs and opportunities of modern
 longevity, 192
 strategies
 adult immunization, health screenings, and
 telehealth options, 191–192
 age-friendly workplaces, 189
 benefits for employee caregivers, 189–190
 different kinds of family caregiving, 191
 health savings accounts (HSAs), 191
 prioritizing healthy aging, 191
 saving and investing early, 190
 tools to plan, save, and invest for a longer life, 189
 working and learning beyond retirement age,
 188–189
Wee1 inhibitor, 15
Werner syndrome (WS), 37, 162
Willingness to pay (WTP), 148–149, 152–154
Wolverine (reversing aging), 151–153
Working age, definition, 187
WS. *See* Werner syndrome
WTP. *See* Willingness to pay